{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:24:54Z","timestamp":1792783494771,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"The University of Sydney","id":[{"id":"https:\/\/ror.org\/0384j8v12","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"DOI":"10.1007\/s40262-026-01687-5","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:06:18Z","timestamp":1792681578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Variability in the Pharmacokinetics of Follitropin Alfa: A Systematic Review"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8213-8710","authenticated-orcid":false,"given":"Ranita","family":"Kirubakaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6422-8683","authenticated-orcid":false,"given":"Toni J. F.","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8756-3994","authenticated-orcid":false,"given":"Beverley J.","family":"Vollenhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6099-3671","authenticated-orcid":false,"given":"Vinayak","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2114-587X","authenticated-orcid":false,"given":"Sophie L.","family":"Stocker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"issue":"3","key":"1687_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2165\/00024677-200403030-00004","volume":"3","author":"S Daya","year":"2004","unstructured":"Daya S. Follicle-stimulating hormone in clinical practice: an update. Treat Endocrinol. 2004;3(3):161\u201371.","journal-title":"Treat Endocrinol"},{"issue":"7","key":"1687_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ph13070136","volume":"13","author":"L Bergandi","year":"2020","unstructured":"Bergandi L, Canosa S, Carosso AR, Paschero C, Gennarelli G, Silvagno F, et al. Human recombinant FSH and its biosimilars: clinical efficacy, safety, and cost-effectiveness in controlled ovarian stimulation for in vitro fertilization. Pharmaceuticals (Basel). 2020;13(7):136.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"1687_CR3","first-page":"139","volume":"24","author":"N Prasetiawati","year":"2023","unstructured":"Prasetiawati N, Sundari AM, Supriyadi A, Sjarbaini H, Tarigan S, Suardana G, et al. The effect of follitropin alfa in controlled ovarian stimulation protocol for in vitro fertilization cycles. J Reprod Infertil. 2023;24(2):139\u201344.","journal-title":"J Reprod Infertil."},{"key":"1687_CR4","unstructured":"Merck KGaA. GONAL-f 450 IU (33 mcg) pen. 2023. https:\/\/www.medicines.org.uk\/emc\/medicine\/14384. Accessed 13 Apr 2025."},{"key":"1687_CR5","unstructured":"European Medicines Agency. Ovaleap. 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ovaleap. Accessed 13 Apr 2025."},{"key":"1687_CR6","unstructured":"European Medicines Agency. Bemfola. 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/bemfola. Accessed 13 Apr 2025."},{"issue":"4","key":"1687_CR7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.6061\/clinics\/2014(04)10","volume":"69","author":"RBF Le\u00e3o","year":"2014","unstructured":"Le\u00e3o RBF, Esteves SC. Gonadotropin therapy in assisted reproduction: an evolutionary perspective from biologics to biotech. Clinics. 2014;69(4):279\u201393.","journal-title":"Clinics"},{"issue":"2","key":"1687_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056189","volume":"8","author":"Q Cai","year":"2013","unstructured":"Cai Q, Wan F, Huang K, Zhang H. Does the number of oocytes retrieved influence pregnancy after fresh embryo transfer? PLoS ONE. 2013;8(2):e56189.","journal-title":"PLoS ONE"},{"issue":"2","key":"1687_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.xfnr.2023.03.002","volume":"4","author":"N Sermondade","year":"2023","unstructured":"Sermondade N, Sonigo C, Pasquier M, Ahdad-Yata N, Fraison E, Grynberg M. Searching for the optimal number of oocytes to reach a live birth after in vitro fertilization: a systematic review with meta-analysis. F&S Rev. 2023;4(2):101\u201315.","journal-title":"F&S Rev"},{"issue":"10","key":"1687_CR10","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1093\/humrep\/det303","volume":"28","author":"J Ji","year":"2013","unstructured":"Ji J, Liu Y, Tong XH, Luo L, Ma J, Chen Z. The optimum number of oocytes in IVF treatment: an analysis of 2455 cycles in China. Hum Reprod. 2013;28(10):2728\u201334.","journal-title":"Hum Reprod"},{"key":"1687_CR11","unstructured":"National Summary Report: Live births per intended egg retrieval (all embryo transfers). 2023. https:\/\/www.sartcorsonline.com\/Csr\/Public?ClinicPKID=0&reportingYear=2023&newReport=True#patient-cumulative. Accessed 16 May 2026."},{"issue":"2","key":"1687_CR12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/humrep\/deae274","volume":"40","author":"KI Kiose","year":"2025","unstructured":"Kiose KI, Storr A, Kolibianakis EM, Mol BW, Venetis CA. Biosimilars versus the originator of follitropin alfa for ovarian stimulation in ART: a systematic review and meta-analysis. Hum Reprod. 2025;40(2):343\u201359.","journal-title":"Hum Reprod"},{"issue":"4","key":"1687_CR13","first-page":"498","volume":"41","author":"B Ata","year":"2025","unstructured":"Ata B, Bosch E, Broer S, Griesinger G, Grynberg M, Kolibianakis E, et al. ESHRE guideline: ovarian stimulation for IVF\/ICSI: an update in 2025. Hum Reprod. 2025;41(4):498\u2013514.","journal-title":"Hum Reprod"},{"key":"1687_CR14","unstructured":"Galatia M, Syoufana R, Edym AJ, Trisetiyono Y. Comparative analysis of follitropin alpha vs. delta: impact on ovarian stimulation outcomes. Sys Rev Pharm. 2024;15(9)"},{"issue":"4","key":"1687_CR15","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0015-0282(16)57467-6","volume":"63","author":"Z Ben-Rafael","year":"1995","unstructured":"Ben-Rafael Z, Levy T, Schoemaker J. Pharmacokinetics of follicle-stimulating hormone: clinical significance. Fertil Steril. 1995;63(4):689\u2013700.","journal-title":"Fertil Steril"},{"issue":"1","key":"1687_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1046\/j.1365-2125.1998.00644.x","volume":"45","author":"MO Karlsson","year":"1998","unstructured":"Karlsson MO, Wade JR, Loumaye E, Munafo A. The population pharmacokinetics of recombinant\u2010and urinary\u2010human follicle stimulating hormone in women. Br J Clin Pharmacol. 1998;45(1):13\u201320.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1687_CR17","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/jcph.1792","volume":"61","author":"AHI Ebid","year":"2021","unstructured":"Ebid AHI, Abdel Motaleb SM, Mostafa MI, Soliman MM. Population PK\u2013PD\u2013PD modeling of recombinant follicle stimulating hormone in in vitro fertilization\/intracytoplasmic sperm injection: implications on dosing and timing of gonadotrophin therapy. J Clin Pharmacol. 2021;61(5):700\u201313.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"1687_CR18","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1080\/09513590.2020.1792437","volume":"37","author":"MC Budani","year":"2021","unstructured":"Budani MC, Fensore S, Di Marzio M, Tiboni GM. Efficacy and safety of follitropin alpha biosimilars compared to their reference product: a meta-analysis. Gynecol Endocrinol. 2021;37(5):406\u201314.","journal-title":"Gynecol Endocrinol"},{"issue":"4","key":"1687_CR19","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s40259-016-0183-4","volume":"30","author":"SM Hoy","year":"2016","unstructured":"Hoy SM. XM17 follitropin alfa (Ovaleap\u00ae): a review in reproductive endocrine disorders. BioDrugs. 2016;30(4):379\u201386.","journal-title":"BioDrugs"},{"issue":"1","key":"1687_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1\u20139.","journal-title":"Syst Rev"},{"key":"1687_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12958-015-0124-y","volume":"13","author":"A Lammerich","year":"2015","unstructured":"Lammerich A, Mueller A, Bias P. Phase I, two-way, crossover study to demonstrate bioequivalence and to compare safety and tolerability of single-dose XM17 vs Gonal-f\u00ae in healthy women after follicle-stimulating hormone downregulation. Reprod Biol Endocrinol. 2015;13:1\u20138.","journal-title":"Reprod Biol Endocrinol"},{"issue":"3","key":"1687_CR22","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s13318-015-0257-6","volume":"41","author":"M Wolzt","year":"2016","unstructured":"Wolzt M, Gouya G, Sator M, Hemetsberger T, Irps C, Rettenbacher M, et al. Comparison of pharmacokinetic and safety profiles between Bemfola\u00ae and Gonal-f\u00ae after subcutaneous application. Eur J Drug Metab Pharmacokinet. 2016;41(3):259\u201365.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"19","key":"1687_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910769","volume":"22","author":"C-C Hsu","year":"2021","unstructured":"Hsu C-C, Hsu L, Hsueh Y-S, Lin C-Y, Chang HH, Hsu C-T. Ovarian folliculogenesis and uterine endometrial receptivity after intermittent vaginal injection of recombinant human follicle-stimulating hormone in infertile women receiving in vitro fertilization and in immature female rats. Int J Mol Sci. 2021;22(19):10769.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1687_CR24","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1002\/jcph.328","volume":"54","author":"H Olsson","year":"2014","unstructured":"Olsson H, Sandstr\u00f6m R, Grundemar L. Different pharmacokinetic and pharmacodynamic properties of recombinant follicle-stimulating hormone (rFSH) derived from a human cell line compared with rFSH from a non-human cell line. J Clin Pharmacol. 2014;54(11):1299\u2013307.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"1687_CR25","doi-asserted-by":"publisher","first-page":"25S","DOI":"10.1016\/S0015-0282(97)00525-6","volume":"69","author":"J-Y le Cotonnec","year":"1998","unstructured":"le Cotonnec J-Y, Porchet HC, Beltrami V, Khan A, Toon S, Rowland M. Clinical pharmacology of recombinant human follicle-stimulating hormone. II. Single doses and steady state pharmacokinetics. Fertil Steril. 1998;69(3):25S-31S.","journal-title":"Fertil Steril"},{"issue":"1","key":"1687_CR26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0015-0282(03)00566-1","volume":"80","author":"MP Steinkampf","year":"2003","unstructured":"Steinkampf MP, Hammond KR, Nichols JE, Slayden SH. Effect of obesity on recombinant follicle-stimulating hormone absorption: subcutaneous versus intramuscular administration. Fertil Steril. 2003;80(1):99\u2013102.","journal-title":"Fertil Steril"},{"issue":"8","key":"1687_CR27","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1093\/humrep\/dex220","volume":"32","author":"K Abd-Elaziz","year":"2017","unstructured":"Abd-Elaziz K, Duijkers I, St\u00f6ckl L, Dietrich B, Klipping C, Eckert K, et al. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials. Hum Reprod. 2017;32(8):1639\u201347.","journal-title":"Hum Reprod"},{"issue":"2","key":"1687_CR28","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0015-0282(97)00503-7","volume":"69","author":"J-Y le Cotonnec","year":"1998","unstructured":"le Cotonnec J-Y, Loumaye E, Porchet H, Beltrami V, Munafo A. Pharmacokinetic and pharmacodynamic interactions between recombinant human luteinizing hormone and recombinant human follicle-stimulating hormone. Fertil Steril. 1998;69(2):201\u20139.","journal-title":"Fertil Steril"},{"key":"1687_CR29","first-page":"12","volume":"4","author":"A Munafo","year":"2001","unstructured":"Munafo A, Bilham W, Trinchard-Lugan I, Buraglio M. Comparative bioavailability and safety of a single dose and a multiple dose formulation of recombinant human follicle stimulating hormone (Gonal-F). J Clin Res. 2001;4:12\u201326.","journal-title":"J Clin Res"},{"key":"1687_CR30","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2147\/IJWH.S83418","volume":"7","author":"A Lammerich","year":"2015","unstructured":"Lammerich A, Bias P, Gertz B. Phase 1 safety, tolerability, and pharmacokinetic study of single ascending doses of XM17 (recombinant human follicle-stimulating hormone) in downregulated healthy women. Int J Womens Health. 2015;7:707\u201316.","journal-title":"Int J Womens Health."},{"issue":"4","key":"1687_CR31","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S0015-0282(16)56644-8","volume":"61","author":"J-Y le Cotonnec","year":"1994","unstructured":"le Cotonnec J-Y, Porchet HC, Beltrami V, Khan A, Toon S, Rowland M. Clinical pharmacology of recombinant human follicle-stimulating hormone (FSH). I. Comparative pharmacokinetics with urinary human FSH. Fertil Steril. 1994;61(4):669\u201378.","journal-title":"Fertil Steril"},{"issue":"4","key":"1687_CR32","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1185\/030079908X291949","volume":"24","author":"M Picard","year":"2008","unstructured":"Picard M, Rossier C, Papasouliotis O, Lugan I. Bioequivalence of recombinant human FSH and recombinant human LH in a fixed 2: 1 combination: two phase I, randomised, crossover studies. Curr Med Res Opin. 2008;24(4):1199\u2013208.","journal-title":"Curr Med Res Opin"},{"key":"1687_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1678830","volume":"16","author":"Z Chen","year":"2025","unstructured":"Chen Z, Yu Q, Feng S, Mo L, Cai L, Du C, et al. A single-center, randomized, open-label, two-period, crossover, fasted bioequivalence study: comparing recombinant human follicle-stimulating hormone for injection (JZB30) with Gonal-f\u00ae in healthy Chinese female participants. Front Pharmacol. 2025;16:1678830.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1687_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11050217","volume":"11","author":"G Leyva-G\u00f3mez","year":"2019","unstructured":"Leyva-G\u00f3mez G, Del Prado-Audelo ML, Ortega-Pe\u00f1a S, Mendoza-Mu\u00f1oz N, Urb\u00e1n-Morl\u00e1n Z, Gonz\u00e1lez-Torres M, et al. Modifications in vaginal microbiota and their influence on drug release: challenges and opportunities. Pharmaceutics. 2019;11(5):217.","journal-title":"Pharmaceutics"},{"issue":"3","key":"1687_CR35","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/(SICI)1520-6017(200003)89:3<297::AID-JPS2>3.0.CO;2-P","volume":"89","author":"CJ Porter","year":"2000","unstructured":"Porter CJ, Charman SA. Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci. 2000;89(3):297\u2013310.","journal-title":"J Pharm Sci"},{"issue":"5","key":"1687_CR36","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.rbmo.2010.06.032","volume":"21","author":"BC Fauser","year":"2010","unstructured":"Fauser BC, Alper MM, Ledger W, Schoolcraft WB, Zandvliet A, Mannaerts BM, et al. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reprod Biomed Online. 2010;21(5):593\u2013601.","journal-title":"Reprod Biomed Online"},{"issue":"2","key":"1687_CR37","doi-asserted-by":"publisher","first-page":"hoaa009","DOI":"10.1093\/hropen\/hoaa009","volume":"2020","author":"OS Teggo","year":"2020","unstructured":"Teggo OS, Bosch E, Broer S, Griesinger G, Grynberg M, Humaidan P, et al. ESHRE guideline: ovarian stimulation for IVF\/ICSI. Hum Reprod Open. 2020;2020(2):hoaa009.","journal-title":"Hum Reprod Open."},{"issue":"7","key":"1687_CR38","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1093\/molehr\/4.7.631","volume":"4","author":"C Anobile","year":"1998","unstructured":"Anobile C, Talbot J, McCann S, Padmanabhan V, Robertson W. Glycoform composition of serum gonadotrophins through the normal menstrual cycle and in the post-menopausal state. Mol Hum Reprod. 1998;4(7):631\u20139.","journal-title":"Mol Hum Reprod"},{"key":"1687_CR39","first-page":"225","volume":"41","author":"J Pierce","year":"1976","unstructured":"Pierce J, Faith M, Giudice L, Reeve J. Structure and structure-function relationships in glycoprotein hormones. Ciba Found Symp. 1976;41:225\u201350.","journal-title":"Ciba Found Symp"},{"issue":"2","key":"1687_CR40","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40268-016-0126-z","volume":"16","author":"TH Rose","year":"2016","unstructured":"Rose TH, R\u00f6shammar D, Erichsen L, Grundemar L, Ottesen JT. Characterisation of population pharmacokinetics and endogenous follicle-stimulating hormone (FSH) levels after multiple dosing of a recombinant human FSH (FE 999049) in healthy women. Drugs R D. 2016;16(2):165\u201372.","journal-title":"Drugs R D"},{"issue":"4","key":"1687_CR41","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/S0015-0282(16)49632-9","volume":"46","author":"Z Ben-Rafael","year":"1986","unstructured":"Ben-Rafael Z, Strauss JF III, Mastroianni L Jr, Flickinger GL. Differences in ovarian stimulation in human menopausal gonadotropin treated woman may be related to follicle-stimulating hormone accumulation. Fertil Steril. 1986;46(4):586\u201392.","journal-title":"Fertil Steril"},{"issue":"3","key":"1687_CR42","doi-asserted-by":"publisher","first-page":"32S","DOI":"10.1016\/S0015-0282(97)00526-8","volume":"69","author":"HC Porchet","year":"1998","unstructured":"Porchet HC, Jean-Yves le Cotonnec M, Ernest LM. Clinical pharmacology of recombinant human follicle-stimulating hormone. III. Pharmacokinetic-pharmacodynamic modeling after repeated subcutaneous administration. Fertil Steril. 1998;69(3):32S-S39.","journal-title":"Fertil Steril"},{"issue":"4","key":"1687_CR43","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/cen.12573","volume":"82","author":"X Huang","year":"2015","unstructured":"Huang X, Li L, Hong L, Zhou W, Shi H, Zhang H, et al. The Ser680Asn polymorphism in the follicle\u2010stimulating hormone receptor gene is associated with the ovarian response in controlled ovarian hyperstimulation. Clin Endocrinol (Oxf). 2015;82(4):577\u201383.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"1687_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/genes14061269","volume":"14","author":"C Alviggi","year":"2023","unstructured":"Alviggi C, Longobardi S, Papaleo E, Santi D, Alfano S, Vanni VS, et al. Genetic variants of gonadotropins and their receptors could influence controlled ovarian stimulation: IVF data from a prospective multicenter study. Genes (Basel). 2023;14(6):1269.","journal-title":"Genes (Basel)"},{"issue":"2","key":"1687_CR45","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10815-011-9673-y","volume":"29","author":"LA Lazaros","year":"2012","unstructured":"Lazaros LA, Hatzi EG, Xita NV, Makrydimas GV, Kaponis AI, Takenaka A, et al. Aromatase (CYP19) gene variants influence ovarian response to standard gonadotrophin stimulation. J Assist Reprod Genet. 2012;29(2):203\u20139.","journal-title":"J Assist Reprod Genet"},{"issue":"10","key":"1687_CR46","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s40262-023-01299-3","volume":"62","author":"X Zhang","year":"2023","unstructured":"Zhang X, Sui Y, Yu L, Zhou M, Zhang C, Liu D, et al. Population pharmacokinetic analysis of follicle-stimulating hormone during ovarian stimulation: relation with weight, prolactin and gene polymorphism in THADA and ADIPOQ. Clin Pharmacokinet. 2023;62(10):1493\u2013507.","journal-title":"Clin Pharmacokinet"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01687-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01687-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01687-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:06:20Z","timestamp":1792681580000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01687-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":46,"alternative-id":["1687"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01687-5","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"9 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Sophie L. Stocker is an Editorial Board member of\n                      Clinical Pharmacokinetics\n                      and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. All other authors have no conflicts of interest to declare that are relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"R.K., T.J.F.M. and S.L.S. designed the study. R.K. and T.J.F.M. performed literature search and were the independent reviewers. R.K. analysed the data and wrote the manuscript. All authors interpreted the data and critically reviewed, edited and approved the final manuscript.","order":6,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}